BioSpace News Archive

FDA

Lumendi Receives FDA 510(k) Clearance for Dilumen C2™

Second Generation Endoscopic Accessory for Endolumenal Procedures

April 23, 2018
·
3 min read
BioMidwest

Prime Therapeutics Finds Poor Adherence to High-Cost Multiple Sclerosis Therapy

Disease-modifying drugs produce significantly fewer relapses, cost-effectiveness in question

April 23, 2018
·
4 min read
Deals

LABORIE Medical Technologies and Cogentix Medical Announce Completion of Acquisition of Cogentix Medical by LABORIE Medical Technologies

LABORIE Medical Technologies (“LABORIE”) and Cogentix Medical, Inc. (NASDAQ: CGNT) (“Cogentix”) today announced the completion of the acquisition by LABORIE of Cogentix through LABORIE’S affiliate Camden Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of LM US Parent, Inc. (“Parent”)

April 23, 2018
·
6 min read
FDA

Sage Therapeutics Submits New Drug Application to U.S. FDA for Intravenous Brexanolone in the Treatment of Postpartum Depression

Brexanolone IV submission is the Company’s first New Drug Application

April 23, 2018
·
6 min read
Business

Kaleido Biosciences Announces Appointment of Joshua Brumm as Chief Financial Officer

Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, today announced the appointment of Joshua Brumm as chief financial officer.

April 23, 2018
·
3 min read
Genetown

New SPINRAZA® (nusinersen) Data Unveiled at AAN Annual Meeting Show Continued Improvement in Motor Function for Broad Age Range and Survival Benefit for Infants

SHINE data illustrates SPINRAZA’s longer-term benefits for infantile-onset SMA, including improvements in motor function and increased event-free survival in participants followed for nearly three years

April 23, 2018
·
11 min read
BioMidwest

Thermo Fisher Scientific Announces $50 Million Investment to Enhance Biologics Capabilities

Project will increase capacity to meet growing customer demand

April 23, 2018
·
3 min read
Pharm Country

SCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis

SCYNEXIS, Inc. announced data presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 21-24, 2018, in Madrid, Spain.

April 23, 2018
·
6 min read